Showing posts with label Biotechnology Products. Show all posts
Showing posts with label Biotechnology Products. Show all posts

Thursday, April 9, 2009

Fast Ricin Detection – Is it Now Possible?

Ricin, a poison found in Castor beans is so potent that even if a small quantity, the size of a grain of salt, gets into your system can kill you. Now, if new research is to be believed, then scientists may have developed a new assay system that detects ricin fast and easy.

Perhaps the most popular incident of ricin poisoning is the 1978 assassination of the Bulgarian dissident Georgi Markov in London. He was reportedly stabbed with an umbrella that lodged a small ricin-coated pellet into his leg that later killed him. With no known antidote available, ricin today, is also feared as a potential bio-terrorism agent.

Till now, scientists had a hard time detecting the toxin. Because it involved multi-step procedures that assessed whether certain compounds were stopping ricin from working or not. But now that may not be necessary.

The New Ricin Detection Assay System

The working of the assay is simple. To check the presence of ricin in suspect samples, they need to be put into a few drops of a mixture of reagents. If the mixture emits light, then ricin is present, else it isn't. Further, the brighter the light emitted or the greater is the luminescence, higher is the concentration of the toxin within the sample. This technique has been developed by researchers at the Albert Einstein College of Medicine of Yeshiva University (AECOM).

It may appear that ricin being a poison only has nefarious applications, but no, just like nuclear energy, which can be used to generate electricity or A-bombs. Ricin too can either be used to kill humans or potentially save them. Because it has been used an cancer drug to kill and destroy cancer cells, however, this research is still in its early stages.

Nevertheless, the new ricin detection assay system should be able arm scientists with the tools that can detect ricin in a jiffy and save lives.

Monday, March 2, 2009

The US Biotech Industry Snapshot

The US biotechnology industry is a vibrant component of the country's economy. Since, the early 1990s the industry has registered a fast growth, with the revenues increasing from $8 billion in 1992 to $39.2 billion in 2003. Further, it is large and complex and is engaged in about 38 areas of sub‐sector elements, from plant and animal life sciences to drug discovery and information technology. The job market forecast of biological technicians, is expected to grow by 28.2 percent between 2004 and 2014.

Read More at: TheMedica

Thursday, February 12, 2009

Survey: Biotechnology Industry will Bounce Back

The biotechnology industry is expected to rebound and outperform healthcare industry and the rest of the market this year, according to findings from an investor perception study released by Thomson Reuters and the Biotechnology Industry Organization (BIO) at the 11th Annual BIO CEO & Investor Conference in New York.

Findings
  • Investors have stated that a company’s cash position is now more important.
  • More than two-thirds in the study expect greater M&A volume in 2009, with major pharmaceutical companies buying biotech of all sizes, and large biotechs buying smaller biotech companies.
  • The study found that most investors are neutral to positive about the policies likely to be pursued by the Obama administration.
  • Investors are particularly hoping for greater consistency and predictability from the FDA where higher safety barriers and insufficient resources are cited as primary reasons for limited drug approvals.
  • Most investors pay little attention to activism in the biotech sector
  • Meeting with management is the most important factor when researching investments, followed by conferences and sell-side research, which is still considered important.
Investors are optimistic about biotech stock performance
  • 70% expect biotech to outperform the rest of the market this year.
  • 59% consider biotech undervalued, while only 4% say the sector is overvalued.
  • 57% expect biotech to rebound during this year; another 30% expect a rebound in 2010.
Investors are less optimistic about research and development
  • 60% state overall productivity in 2009-2011 will be the same as in 2006-2008.
  • Investors see the best opportunities in mid-cap companies with late-stage pipelines
  • 37% of polled investors see opportunity in micro-and small-cap companies, but only 16% favor early stage pipelines over late stage pipelines.
  • 67% of investors state the best investment opportunities lie in oncology while 37% see promise in immunology.

Wednesday, February 4, 2009

The Stem Cell Debate - Is It Settled?

The wait for those in support of embryonic-stem-cell research funding seems to be over, as the President Obama is expected to sign an executive order overriding the federal funding limits put on by the former administration. And leading to the rebirth of stem cell research.

Those against stem cell research contend that stem cells research amounts to abortion, because it moves forward at the expense of destroying human embryos, which are fertilized eggs and in early stages of becoming a baby. And abortion is murder, so stem cells research amounts to killing. So when the Bush administration put a cap on funding it was believed that religious convictions had won over science.

But was it really a victory, especially if you consider that stem cells have the potential to be grown into any type of cell the human body has, and thus making them an excellent resource to treat and manage debilitating diseases such as Alzheimer's, Parkinson's, paralysis, diabetes and more.

Who gets to win or lose?

It seems that despite the convincing power of immorality aspect ascribed to stem cell research, many opinion polls have indicated that a majority of Americans think that stem cell research holds a lot of promise to eventually bring down human suffering than cause it. Perhaps, there would have been some breakthroughs in treatments already, if the big biotechnology product companies hadn't shied away from stem-cell research due to the politics involved.

What's more unpleasant is that a political football match is being played with something as noble as scientific research and which has the potential to save so many lives.

The debate probably isn't settled in the minds of those with the opposing views, and it may never be. But if biotechnology isn't given the respect it deserves, it would choose to grow in a place where it gets the freedom to. For instance, The Shandong Stem Cell Engineering Research Center in China reports, via UPI, that they've successfully cloned five human embryos for medical research!

Posts, Possibly of Interest

Study: Stem Cell Transplant Reverses Multiple Sclerosis

Essential Tips to Import Medical Supplies

2009: Top 9 Issues for Health Industries

Top 10 Cosmetic Surgery Trends for 2009

Top 13 Tips To Prevent Common Cold!